Search Within

Shanu Modi

  1. "Jose Baselga"
Formats
  1. Meeting Abstract (18)
  2. Journal Article (5)
Groups
  1. Breast Medicine Service (23)
  2. Department of Medicine (23)
  3. Solid Tumor Oncology Division (23)
  4. Survivorship Research (20)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (19)
  6. Epidemiology and Biostatistics (18)

More Groups

People
  1. Jose Baselga (23)
  2. Clifford Hudis (20)
  3. Larry Norton (14)
  4. Chau Dang (13)
  5. Diana Lake (13)
  6. Maura Dickler (13)

More People

Years
  1. 2019 (1)
  2. 2018 (3)
  3. 2017 (4)
  4. 2016 (4)
  5. 2015 (6)
  6. 2014 (4)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Cancer Research (8)
  3. Annals of Oncology (2)
  4. Breast Cancer Research and Treatment (1)
  5. Cancer Cell (1)
  6. Clinical Breast Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Association for Cancer Research (8)
  3. Oxford University Press (3)
  4. Cell Press (1)
  5. Elsevier Inc. (1)
  6. Springer (1)

Results (23)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses
    Meeting Abstract

    Tamura, K.; Modi, S.; Tsurutani, J.; Takahashi, S.; Krop, I. E.; Iwata, H.; Wada, R.; Yin, O.; Garimella, T.; Sugihara, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1
    Meeting Abstract

    Baselga, J.; Tamura, K.; Yamashita, T.; Modi, S.; Tokunaga, E.; Ito, Y.; Iwata, H.; Charif, M.; Lee, C. C.; Sugihara, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The genomic landscape of endocrine-resistant advanced breast cancers
    Journal Article

    Razavi, P.; Chang, M. T.; Xu, G.; Bandlamudi, C.; Ross, D. S.; Vasan, N.; Cai, Y.; Bielski, C. M.; Donoghue, M. T. A.; Jonsson, P.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience
    Journal Article

    Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
    The Oncologist (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Meeting Abstract

    Hyman, D. M.; Piha-Paul, S. A.; RodoĢn, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save